Dr. Pabani is a Medical Oncologist at the Tom Baker Cancer Centre, Calgary, AB and is currently appointed as a Clinical Assistant Professor in the Department of Medicine at the University of Calgary. She completed her Internal Medicine and Medical Oncology Training at the University of Alberta and a fellowship in Thoracic Oncology and Immunotherapy at Columbia University in New York City. She is involved in medical education and currently serves as the Assistant Program Director for the Medical Oncology training program in Calgary. Dr. Pabani is actively involved in clinical trials of lung malignancies. She has a research interest in predictors of immunotherapy response and in better managing toxicities associated with immunotherapy. She has received funding from the Alberta Cancer Foundation supporting her research.
Pabani, Aliyah
Medical Oncology
Clinical Assistant Professor
Biography
Area of Focus
Summary of Research
- Shu C, Gainor J, Awad M, Chiuzan C, Pabani A, Garofano R, Stoopler M, Cheng S, White A, Lanuti M, D’Ovidio F, Bacchetta M, Sonett J, Saqi A, Rizvi NA. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020; 21: 786-95
- Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, Chan D, Dusza S, Motzer RJ, Rosenberg JE, Callahan MK, Chapman PB, Geskin L, Lopez AT, Fabbrocini G, Annunziata MC, Kukoyi O, Pabani A, Yang CH, Chung WH, Markova A, Lacouture ME. Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol. 2019; 37(30): 2746-2758
- Camidge R, Pabani A, Miller R, Rizvi NA, Bazhenova L. Management strategies for early onset pulmonary events associated with brigatinib. J Thorac Oncol. 2019; 14(9): 1547-1555
- Meyers DE, Stukalin I Vallerand I, Lewinson RT, Suo A, Dean M, North S, Pabani A, Cheng T, Heng DYC, Bebb DG, Morris DG. The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors. Cancers. 2019; 11(11): 1713
- Pabani A, Butts C. Review of Current Landscape of Immunooncology in Metastatic NSCLC. Current Oncology, 2018; 25(Suppl 1): S94-S102
Area Of Focus
Summary Of Research
- Shu C, Gainor J, Awad M, Chiuzan C, Pabani A, Garofano R, Stoopler M, Cheng S, White A, Lanuti M, D’Ovidio F, Bacchetta M, Sonett J, Saqi A, Rizvi NA. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020; 21: 786-95
- Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, Chan D, Dusza S, Motzer RJ, Rosenberg JE, Callahan MK, Chapman PB, Geskin L, Lopez AT, Fabbrocini G, Annunziata MC, Kukoyi O, Pabani A, Yang CH, Chung WH, Markova A, Lacouture ME. Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol. 2019; 37(30): 2746-2758
- Camidge R, Pabani A, Miller R, Rizvi NA, Bazhenova L. Management strategies for early onset pulmonary events associated with brigatinib. J Thorac Oncol. 2019; 14(9): 1547-1555
- Meyers DE, Stukalin I Vallerand I, Lewinson RT, Suo A, Dean M, North S, Pabani A, Cheng T, Heng DYC, Bebb DG, Morris DG. The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors. Cancers. 2019; 11(11): 1713
- Pabani A, Butts C. Review of Current Landscape of Immunooncology in Metastatic NSCLC. Current Oncology, 2018; 25(Suppl 1): S94-S102